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Two  studies  were  conducted  to conﬁrm  that  a single  oral  dose  of  the  novel  insec-
ticide/acaricide  afoxolaner  is  efﬁcacious  against  existing  infestations  of  Rhipicephalus
sanguineus  sensu  lato  in  dogs  and  can  control  re-infestation  for  up  to  35  days.  Each  study
utilized  16  purpose  bred  adult  dogs  using  a controlled  randomized  block  design.  One  or
two days  prior  to treatment,  all dogs  were  infested  with  50 unfed  adult  ticks.  On  Day  0
one  group  was  treated  with  an  oral  chewable  formulation  of  afoxolaner  at a dose as  close
as possible  to the  minimum  dose  of  2.5  mg/kg.  Weekly  re-infestations  with 50 adult  unfed
ticks  were  repeated  for ﬁve  weeks.  Forty-eight  hours  after  treatment  and  after  each  re-
infestation,  the  number  of remaining  live  ticks  on each  dog  was  counted.  Treatment  with
afoxolaner  resulted  in efﬁcacies  of 98.8–100%  within  48  h  on  existing  tick  infestations,  while
the  efﬁcacy  against  new  tick  infestations  was  >95.7%  over  ﬁve  weeks.
©  2014  The  Authors.  Published  by  Elsevier  B.V.  This  is an  open  access  article  under  the  CC
Y-NC-NB
1. Introduction
Ripicephalus sanguineus sensu lato, the brown dog tick,
most probably originated in Africa, but currently has a
world-wide distribution and is an important parasite of
dogs and other domestic animals (Dantas-Torres, 2010).
This tick species is an important vector of a diverse range
of pathogens, such as Babesia, Cercopithiﬁlaria, Hepato-
zon,  Ehrlichia, and Rickettsia (Dantas-Torres, 2010; Gray
et al., 2013). Control of tick infestations can be a primary
means of preventing these infections (Beugnet and Franc,
2012; Otranto et al., 2009a,b) and limiting other adverse
consequences of tick infestations, such as ﬂaccid paral-
ysis (Blagburn and Dryden, 2009; Otranto et al., 2012).
This article describes a series of 2 studies that were per-
formed to demonstrate the efﬁcacy of afoxolaner, a novel
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insecticide–acaricide, in an oral chewable formulation
(Nexgard®, Merial) against R. sanguineus.
2. Materials and methods
2.1. Experimental design
Two  studies were conducted to assess the efﬁcacy of
afoxolaner against R. sanguineus sensu lato using two tick
strains from different parts of the world. Study A was per-
formed in South Africa, and Study B in Australia. All animal
procedures in this study were reviewed and approved by
the Merial Institutional Animal Care and Use Committee
(USDA, 2008). The design of the studies was in accordance
with the World Association for the Advancement of Vet-
erinary Parasitology (WAAVP) guidelines for evaluating
the efﬁcacy of parasiticides for the treatment, prevention
and control of ﬂea and tick infestation on dogs and cats
(Marchiondo et al., 2013), and was  conducted in accordance
with Good Clinical Practices (EMEA, 2000).
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Table  1
Study design to assess the efﬁcacy of afoxolaner against Rhipicephalus sanguineus sensu lato.
Study and
study location
Dog’s sex Body weight
(kg)
Oral
treatment
Number of ticks for
each infestation
Tick infestation days Tick count days
A. South Africa 7 Males, 9 females 11.0–18.4 Day 0 50 −2, 7, 14, 21, 28, 35 2, 9, 16, 23, 30, 37
B.  Australia 7 Males, 9 females 6.0–30.8 Day 0 50 −1, 7, 14, 21, 28, 35 2, 9, 16, 23, 30, 37
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Table 2
Geometric mean tick counts on control dogs 48 h after treat-
ment/infestation (minimum–maximum count per dog).
Days of infestation Geometric mean tick count
Study A Study B
−1 or −2 27.2 (20–39) 41.4 (29–54)
7  27.8 (16–37) 36.3 (26–47)
14 27.6 (6–42)a 33.9 (23–52
21 26.5 (13–44) 44.6 (34–61)
28 26.2 (10–45)a 44.1 (34–54)
35 28.5 (16–44) 43.6 (33–51)
ranged from 26.2 to 44.6.
In the two studies, afoxolaner was proven efﬁcacious
for treatment of existing or new tick infestations (Table 3).
Table 3
Efﬁcacy of afoxolaner 48 h after treatment/infestation based on geometric
mean tick counts.a
Day of tick infestation % Reduction in live tick counts
Study A Study B
−1 or −2 100 98.8
7  98.7 98.1
14 99.3 99.3
21 98.6 99.4Sixteen mixed breed dogs were included in Study A, and
 each of Beagles, Labrador Retrievers, German Shorthaired
ointers, and Jack Russell Terriers in Study B. All studies fol-
owed a controlled, randomized, block design (Table 1). All
ogs were given a physical examination prior to allocation
o study groups and conﬁrmed to be healthy. They were not
nfested by ticks and did not receive any ectoparasiticide
reatment within the previous 3 months. A pre-treatment
ick infestation was conducted in each study and used for
llocation. For each study, 16 dogs were placed in 8 blocks
f 2 dogs based on descending tick counts. Within each
lock, each dog was randomly assigned to either the control
r the afoxolaner-treated group. Each dog was housed indi-
idually. Daily health observations were made throughout
ach study and the presence or absence of any health issue
r adverse experience was documented. In addition, hourly
ealth observations were made for 4 h following treatment
n Day 0.
Each study used unfed adult ticks from laboratory-
aintained populations. No tick strains were known to be
esistant to any ectoparasiticide.
.2. Experimental procedures
On Day 0, dogs in the afoxolaner treated groups were
dministered the chewable formulation orally. Four sizes
f chews were used containing 11.3 mg,  28.3 mg,  68 mg  or
36 mg  of afoxolaner. The dosing was administered as close
s possible to the minimum effective dose of 2.5 mg/kg
ranging 2.5–3.11 mg/kg). Dogs were infested with 50 adult
icks of approximately equal sex ratio on the day prior to
reatment (Day −1 or −2) and on Days 7, 14, 21, 28 and 35.
orty-eight hours after treatment and 48 h after each of the
ollowing weekly reinfestations, live ticks were removed
nd counted. Tick counts were performed by utilizing ﬁn-
ertips to locate the ticks, followed by visual categorization
s alive/dead. After tick removal, a ﬂea comb was  applied
o the area to ensure removal of all ticks (Marchiondo et al.,
013).
. Data analysis
Total counts of live ticks were transformed to the natu-
al logarithm (count +1) for calculation of geometric means
y treatment group at each time point. Percent reduction
rom the control group mean was calculated for the treated
roup at each post-treatment time point using the formula
(C − T)/C] × 100, where C is the geometric mean for the
ontrol group and T is the geometric mean for the treated
roup. The log counts of the treated group were compared
o the log counts of the untreated control group using ana 7/8 dogs were infested with >12 ticks.
F-test adjusted for the allocation blocks used to randomize
the animals to the treatment groups. The mixed procedure
in SAS® version 9.1.3 was  used for the analysis, with treat-
ment group listed as a ﬁxed effect and the allocation blocks
listed as a random effect. The comparisons were performed
using a two-sided test with a 5% signiﬁcance level.
4. Results
Treated dogs in the two studies accepted the oral chew-
able of afoxolaner with no adverse reactions based on
hourly post-treatment observations and daily observa-
tions. The control dogs were adequately infested by ticks
in both studies (Table 2). According to Marchiondo et al.
(2013) a minimum retention rate of ticks should be at
least 20% in order to get a valid assessment of tick efﬁcacy
between a control and a treated group. The geometric mean
tick infestations for the control dogs in the two studies28 99.3 95.7
35 98.3 96.4
a There was a signiﬁcant difference (p < 0.001) in tick counts between
treated and control dogs at all time points up to Day 35.
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Indeed, the curative efﬁcacies were 98.8–100% against R.
sanguineus within 2 days after treatment, while a prophy-
lactic efﬁcacy > 95.7% was maintained over ﬁve weeks. At
all time points the difference in live tick counts between
treated dogs and controls was statistically signiﬁcant
(P < 0.001).
5. Discussion
Within 48 h of treatment, afoxolaner oral formulation
was highly efﬁcacious against existing infestations by R.
sanguineus. The two studies being independent, it was
not possible to statistically compare the efﬁcacies, but
it does not seem to have any difference between the
results observed on the South African and the Australian
strains of R. sanguineus. The assessment of curative efﬁ-
cacy by counting existing ticks 48 h after treatment is a
standard requirement (Marchiondo et al., 2013). This cura-
tive effect is demonstrated for the ﬁrst time for an oral
product whereas it is well known for many registered
topical spot on formulations (Hunter et al., 2011; Kunkle
et al., 2012). With regard to the curative efﬁcacy, ticks are
already attached and have started their blood meal when
they are killed by acaricidal products. The situation differs
between topical and oral products in the case of new tick
infestations. In that case, topical ectoparasiticides acting
by contact may  kill ticks before attachment while attach-
ment is a prerequisite for a systemic acting drug. In this
study, reinfestations were also controlled for up to ﬁve
weeks in the two studies, with efﬁcacies greater than 95.7%
at 48 h counts. This level of efﬁcacy is similar to what
has been published for topical formulations (Beugnet and
Franc, 2012; Hunter et al., 2011; Kunkle et al., 2012). Afox-
olaner is absorbed rapidly by the intestinal mucosa, and
its plasma concentration peaks within 2–4 h after admin-
istration (Letendre et al., 2014), which ultimately results
in a rapid uptake by the ticks. Further studies should be
undertaken to assess the speed of kill on ticks after their
attachment, knowing that ticks crawl on the skin of their
host for a few hours before attaching. The oral route of
administration offers several advantages over topical treat-
ments. The efﬁcacy of a formulation acting systemically
is not affected by bathing, swimming, rain, or any skin
condition. The dog owners can also handle their animal
immediately.These studies demonstrated that afoxolaner can be used
as an effective agent to treat and control Rhipicephalus
tick infestations with a convenient, monthly oral dosing
schedule.ology 201 (2014) 226–228
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